TABLE OF CONTENT: South African Journal of Diabetes and Vascular Disease

Volume 3, Issue 2, Jun 2006

1. Title: Implementing the South African Hypertension Guideline in diabetes : editorial
   Authors: Seedat, Y.K.
   From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
   Published: 2006
   Pages: p.53-54
   Full text: Click here to order
   Full text: Click here to read online (Login Required)
    
2. Title: The SA Hypertension Guideline 2006 : a major step forward for improved management of hypertension : editorial
   Authors: Rayner, Brian
   From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
   Published: 2006
   Pages: p.57-58
   Full text: Click here to order
   Full text: Click here to read online (Login Required)
    
3. Title: Microvascular disease and glycaemic control : implications of the 2006 South African Hypertension Guideline : editorial
   Authors: Distiller, Larry
   From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
   Published: 2006
   Pages: p.61-62
   Full text: Click here to order
   Full text: Click here to read online (Login Required)
    
4. Title: High sensitivity C-reactive protein in cardiovascular disease and type 2 diabetes : evidence for a clinical role? : editorial
   Authors: Sattar, Naveed
   From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
   Published: 2006
   Pages: p.64-67
   Full text: Click here to order
   Full text: Click here to read online (Login Required)
    
5. Title: Implications of CIBIS III : a commentary : review
   Authors: Willenheimer, Ronnie
   From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
   Published: 2006
   Pages: p.68-73
   Full text: Click here to order
   Full text: Click here to read online (Login Required)
   Abstract: Combined therapy with optimum doses of a beta-blocker and an angiotensin-converting enzyme inhibitor (ACE-I) is the mainstay for the treatment of chronic heart failure (CHF). However, patients cannot be started on full doses of both drugs and treatment has to be initiated one way or the other. The Cardiac Insufficiency Bisoprolol Study (CIBIS) III was the first trial investigating the optimum sequence of initiating treatment of CHF, in terms of mortality and morbidity. CIBIS III compared randomised, open-label initial monotherapy with bisoprolol or enalapril for six months, followed by their combination for six to 24 months, in 1, 010 patients at least 65 years of age, with stable, mildly or moderately symptomatic, systolic CHF. The two strategies were similarly efficacious in terms of the combined primary endpoint of mortality or all-cause hospitalisation, and showed similar safety. The bisoprolol-first approach showed a 28% lower mortality at the end of the monotherapy phase (p=0.24) and a 31% lower mortality at the end of the first year (p=0.06), but a 25% increase in worsening of CHF events (p=0.23). The main conclusion is that, CHF therapy may be started with bisoprolol or enalapril in patients like those in CIBIS III. However, it may be argued that the primary therapeutic goal in the early phase of CHF should be improved survival, whereas the long-term aim, achievable during combined therapy with optimum doses of several drugs, should be improved quality of life, physical function, morbidity and survival. In such case, the CIBIS III findings would tend to support starting CHF therapy with bisoprolol rather than enalapril in stable patients with mild or moderate symptoms.
    
6. Title: Thinking around abdominal obesity and cardiovascular risk : review
   Authors: Broom, Iain
   From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
   Published: 2006
   Pages: p.74-77
   Full text: Click here to order
   Full text: Click here to read online (Login Required)
   Abstract: Obesity, particularly intra-abdominal (visceral) obesity, is a leading cause of cardiovascular disease (CVD), insulin resistance, type 2 diabetes, dyslipidaemia, inflammation and thrombosis. A useful indicator for visceral fat is waist circumference, which is associated with all-cause mortality. Pro-inflammatory adipokines play a causal role in the development of pathologies associated with insulin resistance, type 2 diabetes and CVD.
   In addition to established anti-obesity therapies, namely orlistat and sibutramine, a new type of agent that inhibits the cannabinoid receptor (CB1) is advanced in development to reduce appetite and act predominantly against intra-abdominal adiposity.
    
7. Title: BENEDICT : primary prevention of microalbuminuria in hypertensive type 2 diabetes : review
   Authors: Vora, Jiten; Weston, Clive
   From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
   Published: 2006
   Pages: p.78-81
   Full text: Click here to order
   Full text: Click here to read online (Login Required)
    
8. Title: Treating resistant hypertension in type 2 diabetes : a role for spironolactone? : achieving best practice
   Authors: Stanley, Adrian G.; Swales, Philip; Thurston, Herbert; Williams, Bryan
   From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
   Published: 2006
   Pages: p.82-84
   Full text: Click here to order
   Full text: Click here to read online (Login Required)
    
9. Title: Dual blockade of renin-angiotensin system in diabetic nephropathy : review of literature and local experience : achieving best practice
   Authors: De, Parijat; Das, Gautam; Harley, Karen; Nair, Harikrishan
   From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
   Published: 2006
   Pages: p.85-90
   Full text: Click here to order
   Full text: Click here to read online (Login Required)
   Abstract: Albuminuria and hypertension are predictors of poor renal and cardiovascular outcome in patients with diabetic nephropathy (DN). Intensive treatment requires blockade of the renin-angiotensin system (RAS) by either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), which reduce blood pressure and proteinuria. Combining the two therapies has shown greater benefits than either drug alone to reduce progression of DN.
   Although treatment goals are more likely to be achieved with the combination, this requires close monitoring of serum creatinine and potassium which invariably rise on such therapy.
    
10. Title: Improving therapy for the treatment of cardiometabolic disease : clinical meeting report
    From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
    Published: 2006
    Pages: p.94-98
    Full text: Click here to order
    Full text: Click here to read online (Login Required)
     
11. Title: Eli Lilly sells unit to Batswadi in the first BEE deal by drug giant : diabetes news
    From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
    Published: 2006
    Pages: p.100
    Full text: Click here to order
    Full text: Click here to read online (Login Required)
     
12. Title: Tight glycaemic control benefits critically ill patients during hospitalization : drug trends in diabetes
    From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
    Published: 2006
    Pages: p.102
    Full text: Click here to order
    Full text: Click here to read online (Login Required)
     
13. Title: Caduet, the first 'polypill' on the South African market : drug trends in diabetes
    From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
    Published: 2006
    Pages: p.104-105
    Full text: Click here to order
    Full text: Click here to read online (Login Required)
     
14. Title: Moxonidine well tolerated and effective in the treatment of viscerally obese, non-controlled hypertensive patients : drug trends in diabetes
    From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
    Published: 2006
    Pages: p.106
    Full text: Click here to order
    Full text: Click here to read online (Login Required)
     
15. Title: Biphasic insulin aspart and metformin yield greater HbA1c reductions than basal insulin in type 2 diabetics : drug trends in diabetes
    From: South African Journal of Diabetes and Vascular Disease, Vol 3, Issue 2, Jun
    Published: 2006
    Pages: p.108
    Full text: Click here to order
    Full text: Click here to read online (Login Required)